SNDX - Syndax Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5235.85M
Enterprise Value 3167.07M
Trailing P/E N/A
Forward P/E 1-4.67
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)155.47
Price/Book (mrq)5.35
Enterprise Value/Revenue 3110.13
Enterprise Value/EBITDA 6-2.67

Trading Information

Stock Price History

Beta (3Y Monthly) 2.40
52-Week Change 380.12%
S&P500 52-Week Change 319.27%
52 Week High 311.11
52 Week Low 33.39
50-Day Moving Average 37.04
200-Day Moving Average 38.14

Share Statistics

Avg Vol (3 month) 3146.4k
Avg Vol (10 day) 3143k
Shares Outstanding 527.14M
Float 18.98M
% Held by Insiders 10.01%
% Held by Institutions 172.96%
Shares Short (Nov. 15, 2019) 4647.03k
Short Ratio (Nov. 15, 2019) 45.33
Short % of Float (Nov. 15, 2019) 42.75%
Short % of Shares Outstanding (Nov. 15, 2019) 42.38%
Shares Short (prior month Oct. 15, 2019) 4756.45k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 31, 2018
Most Recent Quarter (mrq)Sep. 30, 2019


Profit Margin 0.00%
Operating Margin (ttm)-4,130.98%

Management Effectiveness

Return on Assets (ttm)-45.32%
Return on Equity (ttm)-112.42%

Income Statement

Revenue (ttm)1.52M
Revenue Per Share (ttm)0.05
Quarterly Revenue Growth (yoy)0.00%
Gross Profit (ttm)1.52M
EBITDA -62.59M
Net Income Avi to Common (ttm)-60.88M
Diluted EPS (ttm)-2.08
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)73.04M
Total Cash Per Share (mrq)2.69
Total Debt (mrq)1M
Total Debt/Equity (mrq)2.28
Current Ratio (mrq)4.09
Book Value Per Share (mrq)1.62

Cash Flow Statement

Operating Cash Flow (ttm)-52.93M
Levered Free Cash Flow (ttm)-29.91M